BIIBBiogen
Is it safe?
Solid, nothing alarming. No accounting flags, quality moderate.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$240K, 90 days to Oct 8, 2026), selling is often routine.
Rock-solid balance sheet, low leverage. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -73% · now at/near its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can BIIB take a bad year?
Biogen carries $2.01B of net debt at 0.93× EBITDA: a load its earnings can carry.
Net debt · as at Q1 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 0.93×
Net debt / EBITDA · 1.63× a year ago · the load is coming down
- Interest cover
- 5.90×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 32%
Annualised volatility · about as steady as the market itself
Details›
- Total debtQ1 2026
- $6.29B
- Cash and short-term investments
- $4.28B
- Net debt
- $2.01B
- EBITDA, trailing twelve months
- $2.16B
- Operating profit, trailing twelve months
- $1.62B
- Debt / equity
- 0.34×
- Total debt / EBITDA
- 2.91×
- Annualised volatilitytwo years of daily moves
- 32%
- Worst drawdown on file
- −73%
- Below its 52-week high
- 1.3%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, General
The closest names by size in the same industry